<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512485</url>
  </required_header>
  <id_info>
    <org_study_id>60281</org_study_id>
    <nct_id>NCT01512485</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions</brief_title>
  <official_title>Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's&#xD;
      Laboratories Ltd, clopidogrel and Bristol-Myers Squibb Company, USA Plavix®, clopidogrel 75&#xD;
      mg tablet under fed condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet&#xD;
      (Dr. Reddy's Laboratories Ltd., India) and Plavix® (Bristol-Myers Squibb Company, USA)&#xD;
      Following a 75 mg Dose In Healthy Subjects Under Fed Conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0.250, 0.500, 0.750, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.0, 16.0, and 24.0 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plavix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel Tablet 75 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel Tablets 75 mg</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_label>Plavix</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects enrolled in this study will be members of the community at large. The recruitment&#xD;
        advertisements may use various media types (e.g. radio, newspaper, Anapharm Web site,&#xD;
        Anapharm volunteers' database). Subjects must meet all of the following criteria to be&#xD;
        included in the study:&#xD;
&#xD;
          -  Male or female, non-smoker, ≥18 and ≤55 years of age.&#xD;
&#xD;
          -  Medically healthy with clinically normal laboratory profile, vital signs and ECG.&#xD;
&#xD;
          -  Capable of consent.&#xD;
&#xD;
          -  BMI ≥19.0 and &lt;30.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant illness or surgery within 4 weeks prior to dosing.&#xD;
&#xD;
          -  Any clinically significant abnormality or abnormal laboratory test results found&#xD;
             during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Clinical Sub-.investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or• heart rate less than 50 or over J00 bpm) at screening.&#xD;
&#xD;
          -  History of significant alcohol abuse or drug abuse within one year prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Regular use of alcohol within six months prior to the screening visit (more than&#xD;
             fourteen units of alcohol per week [J Unit = 150 mL of wine, 360 mL of beer, or 45 mL&#xD;
             of 40% alcohol]), or positive alcohol breath test at screening.&#xD;
&#xD;
          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or&#xD;
             hard drugs (such as cocaine, phencyclidine (PCP] and -crack) within 1 year prior to&#xD;
             the screening visit or positive urine drug screen at screening.&#xD;
&#xD;
          -  History of allergic reactions to clopidogrel or other related drugs.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil, fIuoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to dosing.&#xD;
&#xD;
          -  Clinically significant history or presence of any gastrointestinal pathology (e.g.&#xD;
             chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms&#xD;
             (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of neurological, endocrinal,&#xD;
             cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic&#xD;
             disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the counter products (including natural food supplements, vitamins,&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption and hormonal contraceptives.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Use of any tobacco products in the 3 months preceding drug administration.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Clinical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug (other than hormonal contraceptives)&#xD;
             within 3 months prior to administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
          -  50 mL to 499 mL of whole blood within 30 days,&#xD;
&#xD;
          -  more than 499 mL of whole blood within 56 days prior to drug administration.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening.&#xD;
&#xD;
          -  Breast-feeding subject.&#xD;
&#xD;
          -  Female subjects of childbearing potential having unprotected sexual intercourse with&#xD;
             any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for&#xD;
             at least 6 months) within 14 days prior to study drug administration. Acceptable&#xD;
             methods of contraception are:&#xD;
&#xD;
          -  intra-uterine contraceptive device (placed at least 4 weeks prior to study drug&#xD;
             administration;&#xD;
&#xD;
          -  condom or diaphragm + spermicide;&#xD;
&#xD;
          -  hormonal contraceptives (starting at least 4 weeks prior to study drug&#xD;
             administration).&#xD;
&#xD;
          -  History or known active pathological bleeding (e.g. peptic ulcer, intracranial&#xD;
             hemorrhage).&#xD;
&#xD;
          -  Increased risks of bleeding (e.g. frequent nose bleeding, recent trauma, surgery or&#xD;
             other pathological condition).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Audet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Sainte-Foy (Quebec)</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>crossover</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

